Diagnostic utility of D2-40 and podoplanin in effusion cell blocks

Diagnostic Cytopathology

Volumn 35, Issue 6, 2007, Pages 342-347

  Bhalla, Ritu ^a   Siddiqui, Momin T ^a   Mandich, Daniza ^b   Cartun, Richard W ^b   Fiel Gan, Mary D ^b   Nassar, Aziza ^a   Mandavilli, Srinivas R ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Calretinin; CK5; D2 40; Mesothelioma; Podoplanin

Indexed keywords

CALRETININ; CYTOKERATIN 5; D2 40; MARKER; PODOPLANIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY PRODUCTION; ARTICLE; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EFFUSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT;

EID: 34249716741     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20633     Document Type: Article

References (37)

1. Collins CL, Ordóñez NG, Schaefer R. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-833.
2. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-1408.
3. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 1997;31:25-30.
4. Doglioni C, Dei Tos AP, Laurino L. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
5. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
6. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-148.
7. Ordóñez NG. Value of Cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
8. Amin KM, Litzky LA, Smythe WR. Wilms' tumor 1 (WT1) susceptibility gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
9. Foster MR, Johnson JE, Olson SJ. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-1320.
10. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD 4s immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
11. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
12. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas: A critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
13. Kimura N, Kimura I. Podoplanin as a marker of mesothelioma. Pathol Int 2005;55(2):83-86.
14. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18(1):105-110.
15. Ordóñez NG. Immunohistochemical diagnosis of epithelioid mesotheliomas. Arch Pathol Lab Med 2005;129:1407-1414.
16. Robinson B, Lake R. Advances in malignant mesothelioma. N Engl J Med 2005;353(15):1591-1603.
17. Wang NS, Hung SN, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: An immunohistochemical differentiation from other lung cancers. Cancer 1979;44(3):937-943.
18. Miettinen M, Sarloma-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27(2):150-158.
19. Roberts F, Harper FM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116(2):253-262.
20. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80(3/4):569-578.
21. Baumal R, Bailey D, Giwercman A, Stakkebaek N, Stratis M, Marks A. A novel maturation marker for human Sertoli cells. Int J Androl 1989;12:354-359.
22. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
23. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
24. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 2006;19(1):34-48.
25. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocyles. Bone 1996;18(2):125-132.
26. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells is down-regulated in puromycin nephrosis. Am J Pathol 1997;151(4):1141-1152.
27. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154(2):385-394.
28. Birner P, Obermair A, Schindl M, et al. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 2001;7:93-97.
29. Sinzelle E, Van Huyen JP, Breiteneder-Geleff S, et al. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 2000;37:93-94.
30. Sedivy R, Beck-Mannagetta J, Haverkampf C, Battistutti W, Honigschnable S. Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med 2003;32:455-460.
31. Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 2001;20:29-33.
32. Cunnick GH, Jiang WG, Gomez KF, Mansel RE. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002;17:863-870.
33. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:250-256.
34. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166(3):913-921.
35. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36(4):372-380.
36. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
37. Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: Analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25:610-617.